CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro

Acta Pharmacologica Sinica

Volumn 39, Issue 2, 2018, Pages 222-229

  Liu, Hai Fei ^a   Liu, Hong ^b   Lv, Lin Li ^b   Ma, Kun Ling ^b   Wen, Yi ^b   Chen, Long ^b,c   Liu, Bi Cheng ^b  

^a TAIZHOU FIRST PEOPLE S HOSPITAL   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

CCN3; fibronectin; glomerulosclerosis; MMPs; renal fibrosis; type I collagen

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; GELATINASE A; GELATINASE B; MESSENGER RNA; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; NOV PROTEIN, HUMAN;

ARTICLE; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; KIDNEY FIBROSIS; MESANGIUM CELL; MRNA EXPRESSION LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; GENETICS; METABOLISM; UPREGULATION;

COLLAGEN TYPE I; DOWN-REGULATION; EXTRACELLULAR MATRIX; FIBRONECTINS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MESANGIAL CELLS; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 85041612526     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2017.87     Document Type: Article

References (31)

1. Randles MJ, Woolf AS, Huang JL, Byron A, Humphries JD, Price KL, et al. Genetic background is a key determinant of glomerular extracellular matrix composition and organization. J Am Soc Nephrol 2015; 26: 3021-34.
2. Hornigold N, Craven RA, Keen JN, Johnson T, Banks RE, Mooney AF. Upregulation of Hic-5 in glomerulosclerosis and its regulation of mesangial cell apoptosis. Kidney Int 2010; 77: 329-38.
3. López-Hernández FJ, López-Novoa JM. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res 2012; 347: 141-54.
4. Marchal PO, Kavvadas P, Abed A, Kazazian C, Authier F, Koseki H, et al. Reduced NOV/CCN3 expression limits inflammation and interstitial renal fibrosis after obstructive nephropathy in mice. PLoS One 2015; 10: e0137876.
5. Lennon R, Byron A, Humphries JD, Randles MJ, Carisey A, Murphy S, et al. Global analysis reveals the complexity of the human glomerular extracellular matrix. J Am Soc Nephrol 2014; 25: 939-51.
6. Liu CY, Zhou LL, Cheng Q, Jiang SN, Sheng J, Sun JD, et al. Effect of bradykinin on renal mesangial cell proliferation and extracellular matrix secretion. Genet Mol Res 2014; 13: 490-8.
7. Rupprecht HD, Schöcklmann HO, Sterzel RB. Cell-matrix interactions in the glomerular mesangium. Kidney Int 1996; 49: 1575-82.
8. Hu C, Sun L, Xiao L, Han Y, Fu X, Xiong X, et al. Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy. Curr Med Chem 2015; 22: 2858-70.
9. Riser BL, Cortes P, Yee J. Modelling the effects of vascular stress in mesangial cells. Curr Opin Nephrol Hypertens 2000; 9: 43-7.
10. Li W, Saji S, Sato F, Noda M, Toi M. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects. Int J Biol Markers 2013; 28: 117-30.
11. Coronato S, Laguens G, Di GV. Role of metalloproteinases and their inhibitors in tumors. Medicina (B Aires) 2012; 72: 495-502.
12. Kapoor C, Vaidya S, Wadhwan V, Kaur G, Pathak A. Seesaw of matrix metalloproteinases (MMPs). J Cancer Res Ther 2016; 12: 28-35.
13. Chung B, Hinek A, Keating S, Weksberg R, Shah V, Blaser S, et al. Overgrowth with increased proliferation of fibroblast and matrix metalloproteinase activity related to reduced TIMP1: a newly recognized syndrome. Am J Med Genet A 2012; 158A: 2373-81.
14. Martinerie C, Viegas-Pequignot E, Guenard I, Dutrillaux B, Nguyen VC, Bernheim A, et al. Physical mapping of human loci homologous to the chicken nov proto-oncogene. Oncogene 1992; 7: 2529-34.
15. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003; 178: 169-75.
16. Leask A. Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic. J Cell Commun Signal 2015; 9: 97-8.
17. Ren Z, Hou Y, Ma S, Tao Y, Li J, Cao H, et al. Effects of CCN3 on fibroblast proliferation, apoptosis and extracellular matrix production. Int J Mol Med 2014; 33: 1607-12.
18. Riser BL, Najmabadi F, Garchow K, Barnes JL, Peterson DR, Sukowski EJ. Treatment with the matricellular protein CCN3 blocks and/or reverses fibrosis development in obesity with diabetic nephropathy. Am J Pathol 2014; 184: 2908-21.
19. Riser BL, Najmabadi F, Perbal B, Peterson DR, Rambow JA, Riser ML, et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 2009; 174: 1725-34.
20. van Roeyen CR, Boor P, Borkham-Kamphorst E, Rong S, Kunter U, Martin IV, et al. A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effectst. Am J Pathol 2012; 180: 1979-90.
21. Chen L, Wu YG, Liu D, Lv LL, Zheng M, Ni HF, et al. Urinary mRNA expression of CCN2/CCN3 as a noninvasive marker for monitoring glomerular structure changes in nondiabetic chronic kidney disease. Biomarkers 2012; 17: 714-20.
22. Meng XM, Tang PM, Li J, Lan HY. TGF-β/Smad signaling in renal fibrosis. Front Physiol 2015; 6: 82.
23. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-701.
24. Ahmed AK, Haylor JL, El NAM, Johnson TS. Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int 2007; 71: 755-63.
25. Perbal B. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001; 54: 57-79.
26. van Roeyen CR, Eitner F, Scholl T, Boor P, Kunter U, Planque N, et al. CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int 2008; 73: 86-94.
27. Bigg HF, Rowan AD, Barker MD, Cawston TE. Activity of matrix metalloproteinase-9 against native collagen types I and III. FEBS J 2007; 274: 1246-55.
28. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu ZJ, Balint K, Juhasz I, et al. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 2008; 27: 2552-60.
29. Kular L, Rivat C, Lelongt B, Calmel C, Laurent M, Pohl M, et al. NOV/CCN3 attenuates inflammatory pain through regulation of matrix metalloproteinases-2 and -9. J Neuroinflammation 2012; 9: 36.
30. Lin CG, Chen CC, Leu SJ, Grzeszkiewicz TM, Lau LF. Integrindependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem 2005; 280: 8229-37.
31. Tzeng HE, Chen JC, Tsai CH, Kuo CC, Hsu HC, Hwang WL, et al. CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway. J Cell Physiol 2011; 226: 3181-9.